AL-SHAMASI, Al-Anood; ELKAFFASH, Rozina; MOHAMED, Meram; RAYAN, Menatallah; AL-KHATER, Dhabya; GADEAU, Alain-Pierre; AHMED, Rashid; HASAN, Anwarul; ELDASSOUKI, Hussein; YALCIN, Huseyin Cagatay; ABDUL-GHANI, Muhammad; MRAICHE, Fatima

doi:10.3390/ijms222312677

Langue

Article de revue

Ce document a été publié dans

International Journal of Molecular Sciences. 2021-11-24, vol. 22, n° 23

Résumé en anglais

Abnormality in glucose homeostasis due to hyperglycemia or insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM). These metabolic abnormalities in T2DM lead to cellular dysfunction and the development of diabetic cardiomyopathy leading to heart failure. New antihyperglycemic agents including glucagon-like peptide-1 receptor agonists and the sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to attenuate endothelial dysfunction at the cellular level. In addition, they improved cardiovascular safety by exhibiting cardioprotective effects. The mechanism by which these drugs exert their cardioprotective effects is unknown, although recent studies have shown that cardiovascular homeostasis occurs through the interplay of the sodium-hydrogen exchangers (NHE), specifically NHE1 and NHE3, with SGLT2i. Another theoretical explanation for the cardioprotective effects of SGLT2i is through natriuresis by the kidney. This theory highlights the possible involvement of renal NHE transporters in the management of heart failure. This review outlines the possible mechanisms responsible for causing diabetic cardiomyopathy and discusses the interaction between NHE and SGLT2i in cardiovascular diseases.< Réduire

Mots clés en anglais

Animals

Cardiovascular Diseases

Diabetes Mellitus

Type 2

Diabetic Cardiomyopathies

Humans

Sodium-Glucose Transporter 2 Inhibitors

Sodium-Hydrogen Exchangers

URI

https://oskar-bordeaux.fr/handle/20.500.12278/124665

DOI

http://dx.doi.org/10.3390/ijms222312677

Unités de recherche

Biologie des maladies cardiovasculaires (BMC) - UMR 1034

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche